mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

被引：40

作者：

Cao, Jingsong ^{[1
]}

Choi, Minjung ^{[1
]}

Guadagnin, Eleonora ^{[1
]}

Soty, Maud ^{[2
]}

Silva, Marine ^{[2
]}

Verzieux, Vincent ^{[2
]}

Weisser, Edward ^{[1
]}

Markel, Arianna ^{[1
]}

Zhuo, Jenny ^{[1
]}

Liang, Shi ^{[1
]}

Yin, Ling ^{[1
]}

Frassetto, Andrea ^{[1
]}

Graham, Anne-Renee ^{[3
]}

Burke, Kristine ^{[3
]}

Ketova, Tatiana ^{[3
]}

Mihai, Cosmin ^{[3
]}

Zalinger, Zach ^{[3
]}

Levy, Becca ^{[3
]}

Besin, Gilles ^{[3
]}

Wolfrom, Meredith ^{[3
]}

Tran, Barbara ^{[3
]}

Tunkey, Christopher ^{[3
]}

Owen, Erik ^{[3
]}

Sarkis, Joe ^{[3
]}

Dousis, Athanasios ^{[3
]}

Presnyak, Vladimir ^{[3
]}

Pepin, Christopher ^{[3
]}

Zheng, Wei ^{[3
]}

Ci, Lei ^{[3
]}

Hard, Marjie ^{[3
]}

Miracco, Edward ^{[3
]}

Rice, Lisa ^{[1
]}

Vi Nguyen ^{[1
]}

Zimmer, Mike ^{[1
]}

Rajarajacholan, Uma ^{[1
]}

Finn, Patrick F. ^{[1
]}

Mithieux, Gilles ^{[2
]}

Rajas, Fabienne ^{[2
]}

Martini, Paolo G., V ^{[1
]}

Giangrande, Paloma H. ^{[1
]}

机构：

[1] Moderna Inc, Rare Dis, Cambridge, MA 02139 USA

[2] Univ Claude Bernard Lyon 1, UMR1213, INSERM, Lyon, France

[3] Moderna Inc, Cambridge, MA USA

来源：

NATURE COMMUNICATIONS | 2021年 / 12卷 / 01期

关键词：

HEPATOCELLULAR ADENOMA FORMATION; GENE-THERAPY; GLUCOSE-6-PHOSPHATASE GENE; REPLACEMENT THERAPY; BLOOD-GLUCOSE; CELL THERAPY; MOUSE MODEL; 1A; IA; MUTATIONS;

D O I：

10.1038/s41467-021-23318-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Glycogen Storage Disease 1a (GSD1a) is a rare, inherited metabolic disorder caused by deficiency of glucose 6-phosphatase (G6Pase-alpha). G6Pase-alpha is critical for maintaining interprandial euglycemia. GSD1a patients exhibit life-threatening hypoglycemia and long-term liver complications including hepatocellular adenomas (HCAs) and carcinomas (HCCs). There is no treatment for GSD1a and the current standard-of-care for managing hypoglycemia (Glycosade((R))/modified cornstarch) fails to prevent HCA/HCC risk. Therapeutic modalities such as enzyme replacement therapy and gene therapy are not ideal options for patients due to challenges in drug-delivery, efficacy, and safety. To develop a new treatment for GSD1a capable of addressing both the life-threatening hypoglycemia and HCA/HCC risk, we encapsulated engineered mRNAs encoding human G6Pase-alpha in lipid nanoparticles. We demonstrate the efficacy and safety of our approach in a preclinical murine model that phenotypically resembles the human condition, thus presenting a potential therapy that could have a significant therapeutic impact on the treatment of GSD1a. Glycogen Storage Disease 1a (Gsd1a) is an inherited disorder caused by glucose 6-phosphatase (G6Pase-alpha) deficiency and characterized by hypoglycaemia and high risk of liver cancer. Here the authors develop a mRNA-based G6Pase-alpha delivery therapy that is efficacious and safe in a mouse model of GSD1a.

引用

页数：14

共 50 条

[1] mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease
Jingsong Cao
Minjung Choi
Eleonora Guadagnin
Maud Soty
Marine Silva
Vincent Verzieux
Edward Weisser
Arianna Markel
Jenny Zhuo
Shi Liang
Ling Yin
Andrea Frassetto
Anne-Renee Graham
Kristine Burke
Tatiana Ketova
Cosmin Mihai
Zach Zalinger
Becca Levy
Gilles Besin
Meredith Wolfrom
Barbara Tran
Christopher Tunkey
Erik Owen
Joe Sarkis
Athanasios Dousis
Vladimir Presnyak
Christopher Pepin
Wei Zheng
Lei Ci
Marjie Hard
Edward Miracco
Lisa Rice
Vi Nguyen
Mike Zimmer
Uma Rajarajacholan
Patrick F. Finn
Gilles Mithieux
Fabienne Rajas
Paolo G. V. Martini
Paloma H. Giangrande
Nature Communications, 12
[2] Liver-Directed Gene Therapy for Murine Glycogen Storage Disease Type IB
Kwon, Joonhyun
Cho, Jun-Ho
Lee, Young Mok
Kim, Goo-Young
Anduaga, Javier
Chou, Janice
MOLECULAR THERAPY, 2016, 24 : S64 - S65
[3] Liver-directed gene therapy for murine glycogen storage disease type Ib
Kwon, Joon Hyun
Lee, Young Mok
Cho, Jun-Ho
Kim, Goo-Young
Anduaga, Javier
Starost, Matthew F.
Mansfield, Brian C.
Chou, Janice Y.
HUMAN MOLECULAR GENETICS, 2017, 26 (22) : 4395 - 4405
[4] Adeno-Associated Virus Gene Therapy Prevents Hepatocellular Adenoma in Murine Model of Glycogen Storage Disease Type Ia
Wang, Lili
HEPATOLOGY, 2012, 56 (05) : 1593 - 1595
[5] Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease
Kang, Hye-Ri
Gjorgjieva, Monika
Smith, Stephanie N.
Brooks, Elizabeth D.
Chen, Zelin
Burgess, Shawn M.
Chandler, Randy J.
Waskowicz, Lauren R.
Grady, Kylie M.
Li, Songtao
Mithieux, Gilles
Venditti, Charles P.
Rajas, Fabienne
Koeberl, Dwight D.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 15 : 383 - 391
[6] Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VI
Wilson, Lane H.
Cho, Jun-Ho
Estrella, Ana
Smyth, Joan A.
Wu, Rong
Chengsupanimit, Tayoot
Brown, Laurie M.
Weinstein, David A.
Lee, Young Mok
HEPATOLOGY COMMUNICATIONS, 2019, 3 (11) : 1544 - 1555
[7] AAV Therapy Attenuates Respiratory Dysfunction and Glycogen Accumulation in a Murine Model of Glycogen Storage Disease Type II
Falk, Darin J.
Soustek, Meghan S.
Todd, A. Gary
Mah, Cathryn S.
Cloutier, Denise A.
Clement, Nathalie
Fuller, David D.
Byrne, Barry J.
MOLECULAR THERAPY, 2015, 23 : S159 - S159
[8] NONINVASIVE QUANTIFICATION OF HEPATIC GLYCOGEN BEFORE AND AFTER mRNA THERAPY IN A MOUSE MODEL OF GLYCOGEN STORAGE DISEASE TYPE III
Machado, Michael
Grimm, Andrew
Malvar, Sofi
Saracco, Taira
Zhou, Jin
Zeng, Qing
Yadav, Nirbhay
Poon, Kirsten
MOLECULAR GENETICS AND METABOLISM, 2023, 138 (03) : 69 - 69
[9] GLYCOGEN STORAGE DISEASE OF THE LIVER
MANNERS, DJ
BRITISH MEDICAL JOURNAL, 1955, 2 (AUG6): : 380 - 380
[10] GLYCOGEN STORAGE DISEASE OF THE LIVER
不详
BMJ-BRITISH MEDICAL JOURNAL, 1955, 2 (JUL16): : 189 - 190

← 1 2 3 4 5 →